19 results about "Perillyl alcohol" patented technology

The invention relates to the technical field of health-care products, and particularly discloses a roselle-containing composition and a preparation method thereof, and the roselle-containing composition comprises the following components: a roselle extract, a cocoa extract, coating protein, a fermentation compound and auxiliary materials; the added roselle extract is subjected to multi-step pretreatment, the extraction rate and stability of active ingredients are improved, and the polarity of the roselle extract can be adjusted by adopting a composite solvent for extraction, so that the bioavailability is improved; the added cocoa extract can reduce oxidation of anthocyanin, and the cocoa extract and the roselle extract are synergistically used for reducing blood fat by inhibiting lipase activity and adjusting cholesterol; the fermentation compound can generate urolithin A, pueraria peptide and perillyl alcohol to further assist in reducing blood fat, and the coating protein improves the stability and absorption efficiency of the roselle extract; the auxiliary materials can improve the bioavailability of the active components of the raw materials, and the prepared composition has the effects of inhibiting appetite, promoting lipolysis, inhibiting fat absorption and reducing blood fat through synergistic effects of all the components.

The application discloses a perillyl alcohol phenolic derivative, a preparation method and application thereof. The application provides a perillyl alcohol phenolic derivative with a structure as shown in formula I, a pharmaceutical composition containing the compound with the structure as shown in formula I, and isotopic derivatives, chiral isomers, conformers, different salts, prodrugs, preparations and the like of the compounds. The perillyl alcohol phenolic compound provided by the application can be used in a single drug form in treatment of cancers, and can also be used in combination with other drugs. For example, the perillyl alcohol phenolic compound is combined with a chemotherapy drug or a targeted anti-tumor drug, and has certain therapeutic effect on treatment of lung cancer, breast cancer, brain glioma, liver cancer, gastric cancer, prostate cancer and the like.

The present disclosure refers to therapeutic combinations and pharmaceutical compositions comprising glycolysis inhibitors / modulators and prenyltransferase inhibitors for treating brain tumors. In particular, the disclosure describes therapeutic combinations and pharmaceutical compositions of dichloroacetate (DCA) and perillyl alcohol (POH) useful for treating brain cancers such as glioblastoma multiforme (GBM). Additionally, the disclosure provides methods for treating GBM and other forms of brain cancer using the same.

This invention belongs to the field of biosynthesis, specifically relating to a variant of lysine pyrophosphate diol synthase and the constructed engineered yeast strain for perillaldehyde synthesis. To address the generally low yield of perillaldehyde biosynthesis in existing technologies, this invention mutates and optimizes the lysine pyrophosphate diol synthase to obtain an SsLPPs mutant containing the G379M mutation, which is then used for perillaldehyde synthesis. Simultaneously, to address the genetic instability issues associated with free plasmid expression in some Saccharomyces cerevisiae strains, this invention constructs a perillaldehyde synthesis pathway within the yeast genome. Furthermore, by enhancing the acetyl-CoA synthesis pathway, the MVA pathway, and the perillaldehyde synthesis pathway, and by knocking out some transcriptional repressors, the substrate strain synthesizing perillaldehyde is modified, resulting in a significantly increased yield compared to existing technologies.

The application provides a use of perillaldehyde in preparation of a medicine for treating postpartum lack of lactation, and animal experiments show that perillaldehyde can effectively increase the lactation of postpartum lack of lactation female mice, significantly increase the litter weight growth rate of postpartum lack of lactation female mice, and improve the pathological state of mammary gland tissue of postpartum lack of lactation female mice. In addition, perillaldehyde has good safety and almost no side effects on the body. Therefore, the perillaldehyde described in the application can be used as an active ingredient and applied to preparation of a medicine for treating postpartum lack of lactation, thereby developing a new use of perillaldehyde and providing a new selection for preparation of a medicine for promoting lactation secretion and treating postpartum lack of lactation.

The invention belongs to the technical field of animal disease prevention and control, and discloses application of a traditional Chinese medicine monomer perillyl alcohol in preparation of a medicine for preventing or treating porcine pseudorabies. According to the present invention, the influence of the perillyl alcohol with different concentrations on the activity of BHK-21 cells, the inhibition effect of the perillyl alcohol on the PRV on the BHK-21 cells, the inhibition effect of the perillyl alcohol on the PRV under different action modes, the protection effect of the perillyl alcohol on the PRV infection of mice, and the influence of the perillyl alcohol on inflammatory factors in the serum of the mice are determined; the effect of the perillyl alcohol in the process of inhibiting porcine pseudorabies virus infection is verified, the application value of the perillyl alcohol in resisting the porcine pseudorabies virus is explored, and a theoretical basis and practical guidance are provided for prevention and control of the PRV. Besides, the perillyl alcohol is a medicine with a natural source, has the advantages of safety, few side effects, low metabolic residue and no pollution, and has relatively good popularization and application values.

The invention discloses a perillyl alcohol derivative as well as a preparation method and application thereof. The structural formula of the compound is as shown in formula I in the specification. The preparation method comprises the following steps: (1) reacting perillyl alcohol with p-chloromethyl benzoyl chloride to obtain an esterification reaction intermediate; and (2) carrying out nucleophilic substitution reaction on the esterification reaction intermediate and different substituted piperazines to obtain the target compound I. The compound disclosed by the invention has good activity on gastric cancer cells MKN45 and SGC-7901.

The application belongs to the technical field of animal disease prevention and control, and discloses application of a traditional Chinese medicine monomer, i.e., a perillyl alcohol, in preparation of a medicine for preventing or treating a pseudorabies of pigs. The application verifies the role of the perillyl alcohol in inhibiting a pig pseudorabies virus infection process and explores the application value of the perillyl alcohol in resisting the pig pseudorabies virus, and provides a theoretical basis and practical guidance for prevention and control of the PRV. In addition, the perillyl alcohol is a natural source medicine, has the advantages of safety, few side effects, low metabolic residues and no pollution, and has good popularization and application value.

The present disclosure refers to therapeutic combinations and pharmaceutical compositions comprising glycolysis inhibitors / modulators and prenyltransferase inhibitors for treating brain tumors. In particular, the disclosure describes therapeutic combinations and pharmaceutical compositions of dichloroacetate (DCA) and perillyl alcohol (POH) useful for treating brain cancers such as glioblastoma multiforme (GBM). Additionally, the disclosure provides methods for treating GBM and other forms of brain cancer using the same.

The application discloses a method for recovering perillyl alcohol crude product from perillyl alcohol mother liquor, comprising the following steps: (1) perillyl alcohol in the perillyl alcohol mother liquor is deoximated under the catalysis of acid to generate perillyl aldehyde crude product; (2) perillyl aldehyde is subjected to distillation and impurity removal to obtain perillyl aldehyde with high content; (3) the purified perillyl aldehyde is added into a hydroxylamine solution to perform oximation reaction, and perillyl alcohol crude product can be obtained after the reaction. The method can remove impurities through the distillation method after the perillyl alcohol mother liquor is converted into perillyl aldehyde crude product, and then the oximation is performed again to obtain perillyl alcohol crude product. About 50% of perillyl alcohol in the perillyl alcohol mother liquor can be recovered, and the total yield of perillyl alcohol industrial production is increased.

A formulation including perillyl alcohol and / or derivatives is provided, and a method to inhibit the growth of bacteria, fungi, and yeasts in the presence of blood, bodily fluids, and soil is demonstrated. The use of perillyl alcohol and derivatives, pure or in formulations, is used to inhibit the growth of bacteria, fungi, and yeasts in the presence of blood, bodily fluids, and soil. The formulation is administered to a subject in need thereof an effective amount of a formulation comprising at least one monoterpene as an active ingredient in a concentration between 0.1% to 3%, wherein the formulation remains active in the presence of blood, inorganic material, organic material, and bodily fluids.

The invention relates to the technical field of biological medicine, in particular to combined application of perillaldehyde and givelastat in preparation of a medicine for treating gastric cancer. The invention provides combined application of perillaldehyde and givelastat in preparation of a medicine for treating gastric cancer. Experiments prove that the perillaldehyde and the givelastat are combined to remarkably inhibit growth of gastric cancer cells and promote apoptosis, so that the perillaldehyde and the givelastat have a wide prospect in development of gastric cancer treatment medicines.

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.

The invention discloses a perillaldehyde derivative as well as a preparation method and application thereof. The structural formula of the perillaldehyde derivative is shown in the specification. The compound disclosed by the invention is simple in structure and few in synthesis steps; the compound has an obvious inhibition effect on physalospora piricola, valsa mali, phytophthora capsici, rhizoctonia solani and gaeumannomyces graminis, and can be used as a bactericide for preventing and treating plant diseases.

This invention belongs to the field of biosynthesis, specifically relating to a variant of lysine pyrophosphate diol ester synthase and engineered bacteria for producing perillaldehyde. To address the generally low yield of perillaldehyde biosynthesis in existing technologies, this invention mutates and optimizes lysine pyrophosphate diol ester synthase, obtaining an SsLPPs mutant containing the D374L mutation, and uses this mutant for perillaldehyde synthesis. Simultaneously, to address the genetic instability issues associated with free plasmid expression in some Saccharomyces cerevisiae strains, this invention constructs a perillaldehyde synthesis pathway in the yeast genome. Furthermore, it modifies the substrate bacteria synthesizing perillaldehyde by enhancing the acetyl-CoA synthesis pathway, the MVA pathway, and the perillaldehyde synthesis pathway, and by knocking out some transcriptional repressors, resulting in a significant increase in yield compared to existing technologies.

The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.

The invention belongs to the field of chemical synthesis, and particularly relates to a synthetic method of a natural product D-avocado derived from mature avocado plants. According to the method, 2, 3, 4, 6-tetrabenzyl glucopyranose purchased in a commercial way is subjected to multi-step reaction to synthesize the D-avocado. The invention solves the problem of scarcity of natural sources, provides an efficient chemical total synthesis route which can be implemented on a large scale, thoroughly gets rid of dependence on natural avocado extracts, and provides a stable and reliable material source for subsequent research and application of D-avocado and derivatives thereof.

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

The present application relates to a kind of biosynthesis methods of sclareolide, comprising the following steps: 1) in the fermentation process, every interval one sampling period t1, the content of sclareol in fermentation liquor is sampled and detected, and according to the content of sclareol in fermentation liquor detection value, the feeding speed of sclareol is adjusted;2) the volatilization amount of sclareol in fermentation tail gas is continuously detected, every interval one metering period t2, the volatilization total amount of sclareol is counted once, and the total amount of sclareol feeding in metering period is counted, the ratio of the volatilization total amount of sclareol and the total amount of sclareol feeding is calculated;3) when the ratio is less than threshold value, increase the feeding speed of sclareol.The present application judges the consumption variation of sclareol by continuously monitoring the ratio of the volatilization amount of sclareol in fermentation tail gas and the feeding amount of sclareol, can improve the timeliness of the concentration control of sclareol in fermentation liquor.The conversion rate and yield of biosynthesis sclareolide can be further improved by using the method.